MET and non-small cell lung carcinoma: For example, the anti-MET monoclonal antibody MetMAb, when combined with the epidermal growth factor receptor (EGFR) inhibitor erlotinib, significantly improved progression-free survival (PFS) and overall survival in MET-positive NSCLC patients in a phase II clinical trial (52), In addition, Zhuang et al. (48) reported that anti-MET mAbs enhanced the synergistic effects of radiotherapy and EGFR-targeted therapy, further supporting their combinatorial potential.